NovoBind is an agribiotechnology company developing nanobodies (NBXs) as sustainable alternatives to traditional antimicrobials for use in aquaculture, livestock, and domestic animals. Unlike conventional antimicrobials, NBXs target and neutralize pathogens without killing them, reducing the risk of antibiotic resistance and maintaining microbiome balance.
NovoBind's technology has shown promise in addressing major diseases like acute hepatopancreatic necrosis (AHPND) in shrimp, with NBXs significantly reducing mortality in in vivo trials. The company’s NBX platforms, integrated into feed or probiotics, offer an eco-friendly, cost-effective solution to prevent disease and promote sustainable animal farming practices.
Turn on browser translator feature to read more here in your local language.
Comments